目的：研究脐带血联合单倍体造血干细胞移植（haplo-cord HSCT）治疗血液恶性肿瘤的疗效和安全性。方法：回顾性分析郑州大学附属癌症医院于2017年1月至2021年6月接受haplo-cord HSCT治疗的82例血液恶性肿瘤患者的数据。其中，男性患者52例，女性患者30例，年龄为[M(Q1, Q3)] 29（20，41）岁。所有患者均接受骨髓抑制预处理方案。供者干细胞输入日记为第0天（0 d），注射前一天为第-1天（-1 d），注射后一天为第+1天（+1 d），以此类推。在骨髓抑制预处理方案后，82例患者接受了来自无相关脐血和单倍型供者的外周血和/或骨髓干细胞输注。移植物抗宿主病（GVHD）预防方案为8 mg/kg ATG联合环孢素、多西环素和甲氨蝶呤。对患者进行了移植物成活和移植相关并发症（如GVHD、感染、出血性膀胱炎和长期患者生存）的评估。结果：中性粒细胞着床时间[M(Q1, Q3)]为13（11，15）天，血小板着床时间为15（13，21）天。30天中性粒细胞着床累积发生率为98.8%（81/82），100天血小板着床累积发生率为92.7%（76/82）。急性GVHD（aGVHD）Ⅱ-Ⅳ度和Ⅲ-Ⅳ度的累积发生率分别为24.4%（20/82）和6.1%（5/82）。慢性GVHD在+18个月的累积发生率为13.5%（11/82）。随访时间[M(Q1, Q3)]为26（13，41）个月，移植后3年总生存率（OS）、事件无生存率（EFS）、累积复发率（CIR）和非复发死亡率（NRM）分别为70.5%（95%CI: 59.7%-81.3%）、66.1%（95%CI: 56.1%-76.1%）、6.3%（95%CI: 5.7%-26.9%）和20.8%（95%CI: 12.0%-29.6%）。巨细胞病毒和EBV重激活的累积发生率分别为37.8%（31/82）和14.6%（12/82）。出血性膀胱炎的累积发生率为32.9%（27/82）。结论：haplo-cord HSCT治疗血液恶性肿瘤的疗效可靠，具有快速造血再建、GVHD和病毒再激活的发生率低的特点。

Objective: To investigate the efficacy and safety of umbilical cord blood combined with haploid HSCT (haplo-cord HSCT) in the treatment of hematological malignancies. Methods: The data of 82 patients with hematologic malignancies who received haplo-cord HSCT from January 2017 to June 2021 in the Affiliated Cancer Hospital of Zhengzhou University were retrospectively analyzed. There were 52 male and 30 female patients, aged [M(Q1, Q3)] 29 (20, 41) years. All patients received myeloablative preconditioning regimen. The day of the donor stem cell infusion was recorded as day 0 (0 d), the day before the infusion was recorded as day-1 (-1 d), and the day after the infusion was recorded as day+1 (+1 d), and so on. Eighty-two patients received transfusion of peripheral blood and/or bone marrow stem cells from unrelated cord blood and haplotype donors after the myeloablative preconditioning regimen. The graft-versus-host disease (GVHD) prophylaxis regimen was 8 mg/kg ATG combined with cyclosporine, morte-macrolide, and methotrexate. Patients were evaluated for implantation and the occurrence of transplant-related complications such as GVHD, infection, hemorrhagic cystitis, and long-term patient survival. Results: The time of neutrophil engraftment [M(Q1, Q3)] was 13 (11, 15) days and 15 (13, 21) days for platelet. The 30-day cumulative incidence of neutrophil engraftment was 98.8% (81/82) and 100-day cumulative incidence of platelet engraftment was 92.7% (76/82). The cumulative incidence of acute graft-versus-host disease (aGVHD) in degree Ⅱ-Ⅳ and Ⅲ-Ⅳ was 24.4% (20/82) and 6.1% (5/82), respectively. The cumulative incidence of chronic GVHD in+18 months was 13.5% (11/82). The follow-up time [M(Q1, Q3)] was 26 (13, 41) months, and the overall survival (OS) rate, event-free survival (EFS) rate, cumulative recurrence rate (CIR) and non-recurrence mortality (NRM) rate at 3 years after transplantation were 70.5% (95%CI: 59.7%-81.3%), 66.1% (95%CI: 56.1%-76.1%), 6.3% (95%CI: 5.7%-26.9%) and 20.8% (95%CI: 12.0%-29.6%), respectively. The cumulative incidence of cytomegalovirus and EBV reactivation was 37.8% (31/82) and 14.6% (12/82), respectively. The cumulative incidence of hemorrhagic cystitis was 32.9% (27/82). Conclusion: The efficacy of haplo-cord HSCT in the treatment of hematologic malignancies is reliable, with rapid hematopoietic reconstitution, low incidence of GVHD and virus reactivation.